(Q34361037)

1 August 2017

title

The role of mineralocorticoid receptor function in treatment-resistant depression (English)

1 reference

1 August 2017

Carmine M Pariante

3

0 references

Stafford Lightman

object named as

Stafford Lightman

6

0 references

author name string

Mario F Juruena

1

1 reference

1 August 2017

Mario F Juruena

2

1 reference

1 August 2017

Andrew S Papadopoulos

4

1 reference

1 August 2017

Lucia Poon

5

1 reference

1 August 2017

Anthony J Cleare

7

1 reference

1 August 2017

language of work or name

English

0 references

publication date

31 July 2013

1 reference

Journal of Psychopharmacology

1 August 2017

published in

1 reference

1 August 2017

volume

27

1 reference

1 August 2017

issue

12

1 reference

1 August 2017

page(s)

1169-1179

1 reference

Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Altered glucocorticoid immunoregulation in treatment resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

The childhood experience of care and abuse questionnaire (CECA.Q): validation in a community series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Childhood Experience of Care and Abuse (CECA): a retrospective interview measure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Plasma corticotropin-releasing factor in depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

A randomized trial on mineralocorticoid receptor blockade in men: effects on stress responses, selective attention, and memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Stress and the brain: from adaptation to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Mineralocorticoid receptor also modulates basal activity of hypothalamus-pituitary-adrenocortical system in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Clinical and biological effects of mifepristone treatment for psychotic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Evidence for epidermal growth factor receptor as negative-feedback control in aldosterone-induced Na+ reabsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Cortisol secretion in endogenous depression. II. Time-related functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

The corticosteroid receptor hypothesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

The coming out of the brain mineralocorticoid receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Different responses to dexamethasone and prednisolone in the same depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

The prednisolone suppression test in depression: dose-response and changes with antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Mineralocorticoid receptor function in patients with posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Salivary cortisol in psychoneuroendocrine research: recent developments and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Mental performance in old age dependent on cortisol and genetic variance in the mineralocorticoid and glucocorticoid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Allostasis and allostatic load: implications for neuropsychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

The ratio of cortisol/DHEA in treatment resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Dynamics of glucocorticoid receptor and mineralocorticoid receptor: implications from live cell imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Changes in hypothalamic-pituitary-adrenal axis measures after vagus nerve stimulation therapy in chronic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

The metabolism and biopharmaceutics of spironolactone in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Disruption of mineralocorticoid receptor function increases corticosterone responding to a mild, but not moderate, psychological stressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

A novel prednisolone suppression test for the hypothalamic-pituitary-adrenal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Differences in plasma ACTH and cortisol between depressed patients and normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

The brain mineralocorticoid receptor: greedy for ligand, mysterious in function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

The DST as a predictor of outcome in depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Hypothalamic-pituitary-adrenal axis function in patients with chronic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Elevated resting and exercise-induced cortisol levels after mineralocorticoid receptor blockade with canrenoate in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Mineralocorticoid receptor function in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113499205

21 January 2018

Identifiers

DOI

10.1177/0269881113499205

1 reference

1 August 2017

1 reference